Bausch Health (BHC) Expected to Beat Earnings Estimates: Should You Buy?

Core Viewpoint - Bausch Health (BHC) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending September 2025, with actual results being crucial for near-term stock price movements [1][2]. Earnings Expectations - The upcoming earnings report is scheduled for October 29, and better-than-expected key numbers could lead to a stock price increase, while a miss could result in a decline [2]. - The consensus estimate for quarterly earnings is $1.07 per share, reflecting a year-over-year decrease of 4.5%, while revenues are projected to be $2.6 billion, up 3.8% from the previous year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 7.76%, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Bausch is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +7.73%, suggesting a bullish outlook from analysts [12]. Historical Performance - In the last reported quarter, Bausch was expected to post earnings of $0.97 per share but delivered $0.90, resulting in a surprise of -7.22% [13]. - Over the past four quarters, Bausch has beaten consensus EPS estimates twice [14]. Predictive Indicators - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy) or 2 (Buy) [10]. - Bausch currently holds a Zacks Rank of 2, indicating a higher likelihood of beating the consensus EPS estimate [12].